sorafenib has been researched along with phloretin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (phloretin) | Trials (phloretin) | Recent Studies (post-2010) (phloretin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,223 | 5 | 301 |
| Protein | Taxonomy | sorafenib (IC50) | phloretin (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.3 | |
| Sodium/hydrogen exchanger 9B2 | Homo sapiens (human) | 90 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelgadir, AM; Alhaider, A; Korashy, HM; Saraswati, S; Tanwer, P | 1 |
1 other study(ies) available for sorafenib and phloretin
| Article | Year |
|---|---|
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Molecular Docking Simulation; Phloretin; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; src Homology Domains; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2019 |